May plasma cholesterol level be considered a neoplastic marker in liver disease from cirrhosis to hepatocellular carcinoma?

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 1, 1999, Pages 61-65

  Venturini, I ^a   Amedei, R ^a   Modonesi, G ^a   Cosenza, R ^a   Miglioli, L ^a   Cioni, G ^a   Zeneroli, M L ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Total cholesterol

Indexed keywords

CHOLESTEROL; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CARCINOGENESIS; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; STEROIDOGENESIS; TUMOR CELL;

BIOPSY; CARCINOMA, HEPATOCELLULAR; CHOLESTEROL; COLORIMETRY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032908399     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Beaglehole R, Foulkes MA, Prior IA. Cholesterol and mortality in New Zealand Maoris. Br Med J 1980;1:285-7.
2. Kritz H, Zielinski C, Sinzinger H. Low cholesterol and cancer. J Clin Oncol 1996;14:3043-8.
3. Salonen JT. Risk of cancer and death in relation to serum cholesterol. Am J Epidemiol 1982;116:622-30.
4. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. J Amer Med Ass 1992;267:70-6.
5. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation 1995;92:2396-403.
6. Siperstein MD, Pagan VM, Morris HP. Further studies on the deletion of the cholesterol feedback system in hepatomas. Cancer Res 1966;26:7-11.
7. Santer MA, Waldmann TA, Fallon HJ. Erythrocytosis and hyperlipemia as manifestations of hepatic carcinoma. Arch Intern Med 1967;120:735-9.
8. Goldberg RB, Bersohn I, Kew MC. Hypercholesterolaemia in primary cancer of the liver. S Afr Med J 1975;49:1464-6.
9. Hwang SJ, Lee SD, Chang CF, Wu JC, Tsay SH, Lui WY et al. Hypercholesterolaemia in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1992;5:491-6.
10. Rao KM. The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis. Anticancer Res 1995;15:309-14.
11. Okuda K, Kojiro M, Okuda H. In Schiff L, Schiff ER, editors, Diseases of the liver. Phildadelphia: B. Lippincott Co.; 1993. p. 1236-96.
12. Browner WS, Newman TB, Cummings SR. In Hulley SB, Cummings SR, editors, Designing clinical research. Baltimore: Williams & Wilkins; 1992. p. 87-97.
13. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G,
14. Pagliaro L. Hepatocellular carcinoma a worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962-72.
15. Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80.
16. Tiribelli C, Croce LS, Polo S, Sodde M, Stanta G. Incidence of hepatocellular carcinoma in Italy: what could we learn from autoptic studies? Ital J Gastroenterol 1991;23:448-51.
17. Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, et al. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990;50:3270-3.
18. Lea AJ. Dietary factors associated with death rates from certain neoplasms in man. Lancet 1966;2:332-3.
19. Siperstein MD, Gyde AM, Morris HP. Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatoma. Proc Natl Acad Sci USA 1971;68:315-7.
20. Erickson SK, Cooper AD, Barnard GF, Havel CM, Watson JA, Feingold KR, et al. Regulation of cholesterol metabolism in a slow-growing hepatoma in vivo. Biochim Biophys Acta 1988;960:131-8.
21. Eggens I. Biosynthesis of sterols and dolichol in human hepatomas. Acta Chem Scand B 1987;41:67-9.
22. Rao KN, Elm MS, Kelly RH, Chandar N, Brady EP, Rao B, et al. Hepatic hyperplasia and cancer in rats: metabolic alterations associated with cell growth. Gastroenterology 1997;113:238-9.
23. Iqbal MJ, Wilkinson ML, Johnson PJ, Williams R. Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. Br J Cancer 1983;48:791-6.
24. Porter LE, Van Thiel DH, Eagon PK. Estrogens and progestins as tumour inducers. Semin Liver Dis 1987;7:24-31.
25. Venturini I, Zeneroli ML, Corsi L, Baraldi C, Ferrarese C, Pecora N, et al. Diazepam binding inhibitor and total cholesterol plasma levels in cirrhosis and hepatocellular carcinoma. Regul Pept 1998;74:31-4.
26. Venturini I, Zeneroli ML, Corsi L, Avallone R, Farina F, Alho H, et al. Up-Regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma. Life Sciences 1998;63:1269-80.
27. Krueger KE, Papadopoulos V. Peripheral-type benzodiazepine receptors mediate translocation of cholesterol from outer to inner mitochondrial membranes in adrenocortical cells. J Biol Chem 1990;265:15015-22.
28. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
29. Bolondi L, Benzi G, Santi V, Gaiani S, Li Bassi SL, Zironi G, et al. Relationship between alpha-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population. Ital J Gastroenterol 1990;22:190-4.